RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Metrics to compare | RDHL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRDHLPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.6x | −0.1x | −0.5x | |
PEG Ratio | 0.01 | 0.05 | 0.00 | |
Price/Book | −1.1x | −0.1x | 2.6x | |
Price / LTM Sales | 0.6x | 1.6x | 3.2x | |
Upside (Analyst Target) | - | 134.2% | 42.7% | |
Fair Value Upside | Unlock | 26.8% | 5.8% | Unlock |